The antidiarrheal efficacy of a proprietary amino acid mixture in neuroendocrine tumor (NET) patients.
![](https://flasco.org/wp-content/uploads/enterade-tagline.png)
Clinical data for neuroendocrine tumor patients. Entrinsic recently presented data at ASCO’s Palliative and Supportive Care in Oncology Symposium. Updated clinical results showed that 80% of NET patients reported reduction in diarrhea frequency using enterade. In addition,51% of patients reported more than 50% reduction in frequency. Diarrhea is the most common and debilitating symptom among NET cancer patients. Please click here to access the poster presentation.